Oxidative Stress in Alzheimer’s Disease
Research type
Research Study
Full title
Oxidative Stress in Alzheimer’s Disease
IRAS ID
351835
Contact name
Alison Green
Contact email
Sponsor organisation
Scottish Brain Sciences
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
Alzheimer’s disease is one of the major causes of dementia worldwide. In the UK, nearly 1 million people are thought to have dementia, with this number predicted to increase to 1.4 million by 2040. Currently detecting Alzheimer’s disease is challenging, with limited approved diagnostic tests available for use in clinical practice. Identifying and developing new biological markers (biomarkers) of Alzheimer’s disease is critical for advancing both clinical care and research studies. The aim of this study is to measure biomarkers of oxidative stress and inflammation in blood and cerebrospinal fluid and compare levels between those with and without elevated amyloid levels (a protein associated with Alzheimer’s disease and risk for Alzheimer’s disease dementia). This study is sponsored by Scottish Brain Sciences and is a partnership between Scottish Brain Sciences and MSD. The purpose of this collaboration is based on scientific evidence that increased inflammation is a risk factor for developing AD and it is associated with faster cognitive decline as the disease progresses. One of the aims is to draw any potential links between the levels of toxic amyloid and levels of inflammation.
This study will invite participants enrolled in the IONA Longitudinal Cohort Study (IONA LCS) who have consented to be contacted for other related research studies. In total, 80 participants will be recruited. 40 of these participants will be classified as amyloid positive and 40 will be classified as amyloid negative. This classification is already carried out as part of the IONA LCS protocol and results are disclosed to participants. Participants who are interested in participating will complete the informed consent procedure and provide a new sample of blood for analysis. Some of the newly collected blood will be analysed by the central laboratory team at Scottish Brain Sciences, and some will be sent to MSD for analysis. Participants will also consent for data already collected on them as part of the IONA LCS project, and some of their stored cerebrospinal fluid samples to be sent to MSD for further analysis.
The study has been discussed with our Patient and Public Involvement group (further details submitted with IRAS application).
REC name
London - Camberwell St Giles Research Ethics Committee
REC reference
24/PR/1562
Date of REC Opinion
17 Dec 2024
REC opinion
Favourable Opinion